Dianthus Therapeutics, Inc. /DE/
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(c) Trading Plans. The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the quarter ended December 31, 2025:
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Marino Garcia (President and Chief Executive Officer) | Adoption(November 17, 2025) | Rule 10b5-1 trading arrangement | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to the terms of the trading plan | Through and including December 31, 2026 | Up to 122,918 shares |
| Edward Carr (Chief Accounting Officer) | Adoption(December 11, 2025) | Rule 10b5-1 trading arrangement | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to the terms of the trading plan | Through and including December 31, 2026 | Up to 43,682 shares |
| Paula Soteropoulos (Director) | Adoption (December 23, 2025) | Rule 10b5-1 trading arrangement | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to the terms of the trading plan | Through and including December 31, 2026 | Up to 28,792 shares |
| Ryan Savitz (Executive Vice President, Chief Financial Officer and Chief Business Officer) | Adoption(December 30, 2025) | Rule 10b5-1 trading arrangement | Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to the terms of the trading plan | Through and including March 31, 2027 | Up to 153,840 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.